Search research articles
Contact Us
Filters
Showing results (221-230 of 253) with videos related to
Page
of 26
Sort By:
Antimicrobial Agents and Chemotherapy
|
July 5, 2017
Influence of Mitochondrial Genetics on the Mitochondrial Toxicity of Linezolid in Blood Cells and Skin Nerve Fibers
G Garrabou, À Soriano, T Pinós, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2018
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection
Steven Flamm, K Rajender Reddy, Neddie Zadeikis, et al.
Clinical and Experimental Gastroenterology
|
December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection
Christoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Vaccines
|
April 27, 2026
A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results)
Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|
February 22, 2020
Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR)
E Bouza, J M Aguado, L Alcalá, et al.
Vaccines
|
February 26, 2025
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Joel M Neutel, Rahsan Erdem, Qin Jiang, et al.
Hepatology (Baltimore, Md.)
|
January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment
Fred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)
|
September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
David Wyles, Fred Poordad, Stanley Wang, et al.
The New England Journal of Medicine
|
August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infection
Stefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Plos One
|
December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
Tarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 253) with videos related to
Sort By:
Page
of 26
Antimicrobial Agents and Chemotherapy
|
July 5, 2017
Influence of Mitochondrial Genetics on the Mitochondrial Toxicity of Linezolid in Blood Cells and Skin Nerve Fibers
G Garrabou, À Soriano, T Pinós, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 18, 2018
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection
Steven Flamm, K Rajender Reddy, Neddie Zadeikis, et al.
Clinical and Experimental Gastroenterology
|
December 7, 2016
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection
Christoph Sarrazin, Francesco Castelli, Pietro Andreone, et al.
Vaccines
|
April 27, 2026
A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results)
Rucha Dadhe, Juleen Gayed, Muneeb Iqbal, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|
February 22, 2020
Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR)
E Bouza, J M Aguado, L Alcalá, et al.
Vaccines
|
February 26, 2025
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Joel M Neutel, Rahsan Erdem, Qin Jiang, et al.
Hepatology (Baltimore, Md.)
|
January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment
Fred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)
|
September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
David Wyles, Fred Poordad, Stanley Wang, et al.
The New England Journal of Medicine
|
August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infection
Stefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Plos One
|
December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
Tarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Page
of 26